Invenra Inc. announced a strategic collaboration with Catalent. The collaboration will harness the combined expertise and proprietary technologies of Invenra and Catalent to co-d discover novel bispecific antibody-drug conjugates. Both companies share a commitment to developing novel therapeutic solutions with the potential to make a meaningful impact in the lives of patients.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
56.01 USD | -0.34% | -0.60% | +24.64% |
09:00am | MOVES -Lazard hires veteran healthcare dealmaker Colocci as vice chairman | RE |
05-08 | Earnings Flash (CTLT) CATALENT Posts Q3 Revenue $1.07B | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+24.64% | 10.17B | |
+32.77% | 698B | |
+26.51% | 568B | |
-4.57% | 358B | |
+19.63% | 328B | |
+3.49% | 283B | |
+16.34% | 238B | |
+6.68% | 203B | |
-9.08% | 198B | |
+8.86% | 165B |
- Stock Market
- Equities
- CTLT Stock
- News Catalent, Inc.
- Invenra Inc. Announces Strategic Collaboration with Catalent to Co-Discover Novel Bispecific ADCs